Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio EssenceBIOE 31 Gross Margin % is 63.67% as of Mar. 2026, which is 48% above its 10-year median of 43.15. GuruFocus rates BIOE with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 943 Drug Manufacturers companies, Bio Essence ranks better than 85.15% on this metric.
The historical rank and industry rank for Bio Essence's Gross Margin % or its related term are showing as below:
BIOE'
s Gross Margin % Range Over the Past 10 Years
Min: 20.82 Med: 43.15 Max: 75.24
Current: 72.69
During the past 7 years, the highestGross Margin % of Bio Essence was 75.24%. The lowest was 20.82%. And the median was 43.15%.
BIOE's Gross Margin % is ranked better than 85.15% of 943
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs BIOE: 72.69
Bio Essence had a gross margin of 63.67% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Bio Essence was 0.00% per year.
Bio Essence (OTCPK:BIOE) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Bio Essence had a gross margin of 63.67% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Bio Essence Gross Margin % Related Terms
Bio Essence Gross Margin % Historical Data
* Premium members only.
The historical data trend for Bio Essence's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BIOE vs BFRI, APUS, CABR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bio Essence's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio Essence Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bio Essence's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Bio Essence's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Bio Essence (BIOE) has a Gross Margin % of 63.67% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Bio Essence and its competitors. This is 48% above median its historical median of 43.15. Over the past decade, Bio Essence's Gross Margin % has ranged from 20.82 to 75.24. According to the industry distribution chart, Bio Essence ranks #140 out of 943 companies in the Drug Manufacturers industry, placing it in the top 14.8%.
Is Bio Essence's Gross Margin % too high?
Bio Essence's current Gross Margin % of 63.67% is 48% above median its 10-year median of 43.15. Over the past 10 years, this metric has ranged from a low of 20.82 to a high of 75.24. The Drug Manufacturers industry median Gross Margin % is 48.54. Bio Essence's value of 63.67% is 31.2% above this industry median. Based on the distribution chart, Bio Essence ranks #140 out of 943 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bio Essence has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Bio Essence's Gross Margin % compare to BFRI and APUS?
According to the Drug Manufacturers industry distribution chart, Bio Essence ranks #140 out of 943 companies for Gross Margin %. This places Bio Essence in the top 15% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Bio Essence's value of 63.67% is 31.2% above this benchmark. Historically, Bio Essence's own Gross Margin % has ranged from 20.82 to 75.24 over the past decade. While the company's 10-year median is 43.15 vs. the industry median of 48.54, Bio Essence has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio Essence's current Gross Margin % of 63.67% is 31.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Bio Essence and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio Essence's current Gross Margin % is 63.67%, which is 48% above median its own 10-year median of 43.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Essence stock overvalued right now?
Bio Essence (BIOE) has a current Gross Margin % of 63.67%. The current Gross Margin % is 63.67%, which is 48% above median its 10-year median of 43.15 and 31.2% above the Drug Manufacturers industry median of 48.54. Bio Essence's overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Bio Essence (BIOE), the current Gross Margin % is 63.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio Essence Corp is an herbal health, diet, and nutrition company. The Company's mission is to provide herbal health, diet, and vitamin nutritional supplements. The primary focus of BEP was producing products for BEH and McBE, along with providing original equipment manufacturing and private label services to other companies. BEH targeted and developed traditional Chinese medicines (TCM) in the form of single herbs, granules, pills, and tablets. It also offered specially formulated dietary supplements and medical food. The Company operates in one business and industry segment: the manufacture / OEM and sale of health supplement products. The group's products are RED Yeast Rice Plus, Regenva, MediDrink, and Nufargo.
31GF Score
Get the complete analysis for BIOE
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIOE has been successfully added to your 
